ArticleBiomedical optics express2025
Transforming hyperspectral data into insight: the DREAM approach for pathology.
Article in Biomedical optics express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transforming hyperspectral data into insight: the DREAM approach for pathology.Biomedical optics express · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quantitative pathology remains limited due to the need for chemical staining and subjective interpretation of tissue features. Autofluorescence imaging offers a label-free alternative; however, high-dimensional excitation-emission datasets pose challenges for visualization and reproducible analysis. Here, we present Dimensionality Reduction for Enhanced Autofluorescence Microscopy (DREAM), a method that condenses multi-excitation emission spectra into a compact, information-rich format using phasor-based tools. Applied to unstained esophageal tissue samples, DREAM enables high-contrast visualizations that distinguish key histological structures without the need for exogenous labeling. Quantitative assessments across multiple datasets show DREAM improves colorfulness, sharpness, and consistency over single-laser acquisitions, supporting its potential to advance objective, label-free diagnostics through enhanced spectral visualization.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.